Dexamethasone ameliorates severe pneumonia but slightly enhances viral replication in the lungs of SARS-CoV-2-infected Syrian hamsters

Lunzhi Yuan1,7, Ming Zhou1,7, Jian Ma1,7, Xuan Liu1, Peiwen Chen2,3,4, Huachen Zhu2,3,4, Qiyi Tang5, Tong Cheng5,6,8, Yi Guan2,3,8,9 and Ningshao Xia1,6,9

© The Author(s) 2021

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in more than 230 million cases and over four million deaths worldwide. Furthermore, multiple emerging SARS-CoV-2 variants have shown enhanced infectivity, transmissibility, pathogenicity and ability to escape neutralization by vaccine-induced humoral immunity [1]. The antibody resistance of SARS-CoV-2 variants constitutes a challenge for current vaccines and therapeutic antibodies. No specific antiviral is currently available for coronavirus in humans [2]. Although remdesivir was approved by the FDA for the treatment of SARS-CoV-2 infection, the therapeutic effect is limited, particularly for critical cases with severe pneumonia. Therefore, a more effective anti-SARS-CoV-2 regimen is needed to end the COVID-19 pandemic.

SARS-CoV-2-induced immunological disorder is the leading cause of severe pneumonia and death in critical cases. After SARS-CoV-2 infection, excessive and imbalanced immune responses result in dysregulated secretion of proinflammatory cytokines, such as tumor-necrosis factor α (TNF-α), interferon γ (IFN-γ), interleukin 6 (IL-6) and IL-10, which largely increase the severity of pneumonia and lead to multiorgan failure. The hyperactivated and dysregulated immune system in critical cases necessitates anti-inflammatory immunotherapy [3]. Recently, several clinical studies demonstrated that the FDA-approved glucocorticoid drug dexamethasone is able to reduce disease severity and mortality in hospitalized human patients with SARS-CoV-2 infection [4, 5]. In contrast to newly developed drugs, dexamethasone has unique advantages, including being inexpensive and widely available and having 60 years of safety profiling [6]. However, the mechanism of the effects of dexamethasone treatment on SARS-CoV-2-induced severe pneumonia is not clear. Moreover, the side effects, intervention time point, and duration of dexamethasone treatment need further evaluation in clinical studies and animal models.

To mimic patients with severe pneumonia caused by SARS-CoV-2, Syrian hamsters were intranasally infected with 1 × 10^4 plaque-forming units (PFUs) of an ancestral SARS-CoV-2 strain (AP-8) as previously described [7, 8]. SARS-CoV-2-infected hamsters were untreated or treated with 1, 3, or 5 doses of dexamethasone (1 mg/kg per dose) via intraperitoneal injection (Fig. 1a). SARS-CoV-2-infected hamsters without dexamethasone treatment (control group) exhibited progressive mean body-weight loss of up to 13.4 ± 1.8% from 1 to 7 days post infection (dpi) (Fig. 1b). However, SARS-CoV-2-infected hamsters treated with 1, 3, or 5 doses of dexamethasone exhibited body-weight loss of 9.8 ± 2.1%, 7.1 ± 1.5% and 1.9 ± 2.3% at 7 dpi, respectively (Fig. 1b). To evaluate the lung-pathogenesis severity, viral load, and host immune response, all of the hamsters were euthanized at 7 dpi. Lung lobes were collected and fixed in formalin for systematic pathological analysis. Hematoxylin and eosin (H&E) staining of lung lobes revealed that in contrast to the noninfected (mock) hamsters, SARS-CoV-2-infected hamsters without dexamethasone treatment had typical features of severe pneumonia, including increased lung-lobe consolidation and alveolar destruction, diffusive inflammation, protein-rich fluid exudate, hyaline-membrane formation and severe pulmonary hemorrhage (Fig. 1c and Supplementary Fig. 1). H&E staining of the lung lobes of SARS-CoV-2-infected hamsters treated with dexamethasone showed alleviation of the lung pathological changes (Fig. 1c and Supplementary Fig. 1). Notably, diffusive lung injury was not observed at 7 dpi in the lung lobes of SARS-CoV-2-infected hamsters treated with five doses of dexamethasone (Fig. 1c and Supplementary Fig. 1). In addition, the severity of lung pathogenesis was quantified by a comprehensive pathological score based on alveolar septum thickening and consolidation, hemorrhage, exudation, pulmonary edema and mucus, inflammatory-cell recruitment and infiltration among all of the hamster lung lobes (Fig. 1d and Table S1).

1State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, Fujian, China. 2State Key Laboratory of Emerging Infectious Diseases, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, SAR, China. 3Guangdong-Hong Kong Joint Laboratory of Emerging Infectious Diseases/ Joint Laboratory for International Collaboration in Virology and Emerging Infectious Diseases, Joint Institute of Virology (STU/HKU), Shantou University, Shantou, Guangdong, China. 4EKIH Pathogen Research Institute, Futian District, Shenzhen, Guangdong, China. 5Department of Microbiology, Howard University College of Medicine, Washington, DC, USA. 6Research Unit of Frontier Technology of Structural Vaccinology, Chinese Academy of Medical Sciences, Xiamen, Fujian, China. 7These authors contributed equally: Lunzhi Yuan, Ming Zhou, Jian Ma.

Published online: 5 January 2022

Received: 2 October 2021 Accepted: 8 October 2021
Current evidence suggests that dysregulated production of proinflammatory cytokines plays an important role in the immunopathology progression of SARS-CoV-2 infection [9]. To determine whether dexamethasone is able to suppress excessive proinflammatory cytokine expression after SARS-CoV-2 infection, the mRNA levels of several proinflammatory cytokines in homogenized lung tissues collected at 7 dpi were measured by real-time polymerase chain reaction (RT–PCR). Compared with the mock hamsters, the SARS-CoV-2-infected hamsters showed an approximately 1000- to 50,000-fold increase in the mRNA levels of IL-4, IL-6, IL-10, IL-13, TNF-α and IFN-γ in homogenized lung tissues collected at 7 dpi (Fig. 1e). However, these increased mRNA levels of proinflammatory cytokines, which are related to cytokine storms, were significantly suppressed by dexamethasone.
Next, we analyzed viral replication in respiratory-tract organs, including the turbinate, trachea and lung by RT–PCR, which amplified SARS-CoV-2 open-reading frame 1ab (ORF1ab) and nucleocapsid protein (NP) for detection of viral RNA load in the homogenized tissues collected at 7 dpi. Compared with SARS-CoV-2-infected hamsters without dexamethasone treatment, 5-dose dexamethasone-treated hamsters had higher levels of viral RNA in the turbinate, trachea, and middle and caudal lung (Fig. 1f and Supplementary Fig. 2), but only the increases in the lungs were statistically significant. To test whether dexamethasone treatment is able to alter antibody responses, we analyzed the levels of specific antibodies against the SARS-CoV-2 receptor-binding domain (RBD) and the neutralizing-antibody (NAb) titers in the serum of hamsters at 7 dpi. In brief, SARS-CoV-2-infected hamsters treated with dexamethasone showed lower serum anti-RBD antibody and NAb titers (Supplementary Fig. 3) than those not treated. The decrease in antibody levels in serum was related to the duration of dexamethasone treatment, suggesting a high correlation between the increase in viral RNA in lung tissue and treatment with dexamethasone. Indeed, the average viral RNA load in lung tissues had an inverted proportional relationship with the NAb titer at 7 dpi (Fig. 1g). These results demonstrated that dexamethasone slightly enhances viral replication in lung tissues because of attenuation of antibody responses. In addition, the D614G mutation in the SARS-CoV-2 variant enhanced its pathogenicity in hamsters. Fortunately, five doses of dexamethasone were adequate to rescue the infected hamsters from death (Supplementary Fig. 4 and Table S2).

The progression of SARS-CoV-2-induced severe pneumonia is driven by virus replication-induced immunopathology. Therefore, both antiviral and anti-inflammatory countermeasures are important for the clinical care in critical cases. The overarching findings of this study are that the immunosuppressive properties of dexamethasone may be a double-edged sword for therapy for SARS-CoV-2 infection: suppression of inflammation but enhancement of viral replication. In SARS-CoV-2-infected hamsters, dexamethasone treatment induced attenuation of serum-neutralizing antibody and RBD-specific antibody titers, which resulted in a slight enhancement of viral replication in the lung. To offset this drawback, it is necessary to combine dexamethasone treatment with antiviral agents such as remdesivir and potent antibody cocktails. In the hamster model, dexamethasone has been demonstrated to be an efficient anti-inflammatory agent to treat SARS-CoV-2-induced severe pneumonia (Supplementary Fig. 5). In addition, our data highlighted that the timing and duration of dexamethasone treatment might have an impact on its therapeutic effect. Overall, we revealed the advantages and disadvantages of dexamethasone treatment, which may guide its clinical application in the foreseeable future.

REFERENCES
1. Garcia-Beltran WF, Lam EC, St Denis K, Nittido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021;184:2523–2523. https://doi.org/10.1016/j.cell.2021.04.006. (vol 184, pg 2372, 2021).
2. Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronavirus - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;15:327–47. https://doi.org/10.1038/nrd.2015.37.
3. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:269–70. https://doi.org/10.1038/s41577-020-0308-3.
4. Benfield T, Bodilsen J, Brieghel C, Harboe ZB, Hellesberg M, Holm C, et al. Improved survival among hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. A nationwide population-based cohort study. Clin Infect Dis. 2021. https://doi.org/10.1093/cid/ciab536.
5. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mahtam M, Bell JL, et al. Dexamethasone in hospitalized patients with covid-19. N. Engl J Med. 2021;384:693–704. https://doi.org/10.1056/NEJMoa2102143.
6. Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020;20:587–8. https://doi.org/10.1038/s41577-020-00421-x.
7. Yuan L, Zhu H, Zou M, Ma J, Chen R, Yu L, et al. Persisting lung pathogenesis and minimal residual virus in hamster after acute COVID-19. Protein Cell. 2021. https://doi.org/10.1007/s13238-021-00874-3.
8. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20:587–8. https://doi.org/10.1038/s41577-021-00552-0.
9. Yang L, Xie T, Tu Z, Fu J, Xu D, Zhou Y. The signal pathways and treatment of cytokine storm in COVID-19. Signal Transduct Target Ther. 2021;6:255. https://doi.org/10.1038/s41392-021-00679-0.

ACKNOWLEDGEMENTS
This work was supported by grants from the National Science Key Research and Development Project (No. 2020YFC0842600), National Natural Science Foundation of China (No. 82002139), China Postdoctoral Science Foundation (No. 2020T133062, No. 2020M682092), and the CAMS Innovation Fund for Medical Sciences (No. 2019IK2022). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the paper.

AUTHOR CONTRIBUTIONS
YLZ, ZM, and MJ contributed equally to this study. ZHC and CPW provided the virus stocks. YLZ, ZM and MJ performed the animal experiments and collected samples. ZM, MJ and LX performed sample analysis. ZHC and TQY edited the paper and provided valuable suggestions for study design and data analysis. CT, YG, and XNS supervised the study. All authors have approved the final version of this paper.

COMPETING INTERESTS
The authors declare no competing interest.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41423-021-00793-7.
Correspondence and requests for materials should be addressed to Tong Cheng, Yi Guan or Ningshao Xia. Reprints and permission information is available at http://www.nature.com/reprints

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021